COMPANY:

Theragen Bio

"Theragen Bio and Korea University Ansan Hospital (KUAH) said they would team up to utilize precision genomic data...They will also collaborate on cutting-edge precision medical services such as single-cell genome and spatial transcriptome analysis." "

"Agilent Technologies...announced the recent signing of a Memorandum of Understanding (MOU) with Theragen Bio in South Korea to boost precision oncology through advancing bioinformatic (BI) solutions. As part of the partnership agreement, Agilent and Theragen Bio will combine their respective strengths in cancer genomic profiling (CGP) design, engineering knowledge and software expertise to drive localized analysis capabilities and accelerate treatment decisions...Agilent’s SureSelect Cancer CGP assay uses next generation sequencing (NGS) to transform translational research and clinical trials in oncology through high throughput sequencing of DNA and RNA bases in parallel, while reducing hands-on time to maximize lab efficiency."